Loniten Side Effects
Generic name: minoxidil
Note: This document contains side effect information about minoxidil. Some of the dosage forms listed on this page may not apply to the brand name Loniten.
Some side effects of Loniten may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to minoxidil: oral tablet
Along with its needed effects, minoxidil (the active ingredient contained in Loniten) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking minoxidil:More common
- Fast or irregular heartbeat
- weight gain (rapid) of more than 5 pounds (2 pounds in children)
- Chest pain
- shortness of breath
Check with your doctor as soon as possible if any of the following side effects occur while taking minoxidil:More common
- flushing or redness of skin
- swelling of feet or lower legs
- Numbness or tingling of hands, feet, or face
- Skin rash and itching
Some side effects of minoxidil may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Increase in hair growth, usually on face, arms, and back
- Breast tenderness in males and females
This medicine causes a temporary increase in hair growth in most people. Hair may grow longer and darker in both men and women. This may first be noticed on the face several weeks after you start taking minoxidil. Later, new hair growth may be noticed on the back, arms, legs, and scalp. Talk to your doctor about shaving or using a hair remover during this time. After treatment with minoxidil has ended, the hair will stop growing, although it may take several months for the new hair growth to go away.
For Healthcare Professionals
Applies to minoxidil: compounding powder, oral tablet
Minoxidil is usually administered with a beta-blocker to counteract the increased cardiac output and cardiac work associated with profound minoxidil-induced vasodilation and with a loop diuretic to counteract the sodium and water retaining properties of minoxidil (the active ingredient contained in Loniten)
Cardiovascular side effects are related to peripheral vasodilation and sodium and water retention, and include hypotension, sinus tachycardia, provocation of angina, edema, and weight gain. Edema is expected without concomitant use of a diuretic agent.
Pericardial effusions occur in up to 5% of patients and may be more likely in patients with renal insufficiency. Reversible, nonspecific ST-T wave electrocardiographic changes occur in 30% to 90% of patients.
The hypotensive effect of minoxidil may last for days after drug discontinuation.
The mechanism of minoxidil-associated angina is not known. Theories include a coronary "steal" phenomenon secondary to coronary vasodilation, resulting in relative ischemia to hypoperfused areas of myocardium and increased cardiac work secondary to minoxidil-induced reflex tachycardia.
Nonspecific ST-T wave changes are not necessarily associated with cardiac disease.
The incidence of pericardial effusion in minoxidil-treated uremic patients is greater than that expected in non-treated uremic patients. Tamponade is reported in up to 23% of minoxidil-associated pericardial effusions, which has been fatal in rare cases.
Rare cases of pulmonary hypertension have been associated with minoxidil. Pulmonary hypertension is thought to be due to a minoxidil-induced increase in cardiac output and in pulmonary blood flow.
Hemorrhagic and degenerative lesions of the right atrium and focal necrosis of the left ventricular papillary muscle have been described in dog studies, but not in monkeys. No data are available in humans.
Hypertrichosis usually presents as elongated and hyperpigmented new hair. Hypertrichosis is reversible. Hypertrichosis usually begins at the temples, forehead, and between the eyebrows, but may involve the trunk, extremities, and scalp. Some studies have shown hypertrichosis to occur at lower doses in females, although it may be that females were more distressed by this side effect, and presented these findings earlier than men did.
Dermatologic side effects are common. Hypertrichosis occurs in 30% to 80% of patients within the first 3 to 6 weeks of therapy. A fatal case of toxic epidermal necrolysis has also been reported.
Hypersensitivity reactions such as contact dermatitis, desquamative and bullous rashes, and Stevens-Johnson syndrome have been reported in less than 1% of patients.
Gastrointestinal side effects are uncommon and include nausea and vomiting.
Hematologic side effects, such as decreased hematocrit and hemoglobin, are usually related to dilution from minoxidil-induced sodium and water retention.
A case of thrombocytopenia associated with minoxidil, which recurred upon rechallenge, has been reported.
A case of bilateral optic neuritis, followed by atrophy and vision loss, was associated with minoxidil (the active ingredient contained in Loniten) despite the fact that the patient was taking other medications as well.
Nervous system side effects are usually limited to headache in approximately 6% and dizziness in approximately 2% of patients. Rare cases of general fatigue have been reported.
Immunologic side effects are extremely rare.
A case of a lupus syndrome associated with the development of a speckled ANA pattern has been associated with minoxidil. The patient had previously taken hydralazine, but did not test positive for ANA until after minoxidil was substituted for hydralazine.
Endocrine side effects include at least one case of pseudoacromegaly. A case of pseudoacromegaly which resulted from long-term (10 years) use of minoxidil (the active ingredient contained in Loniten) (50 mg/day) has been reported.
More Loniten resources
- Loniten Prescribing Information (FDA)
- Loniten Concise Consumer Information (Cerner Multum)
- Loniten Advanced Consumer (Micromedex) - Includes Dosage Information
- Minoxidil Prescribing Information (FDA)
- Minoxidil Professional Patient Advice (Wolters Kluwer)
- minoxidil MedFacts Consumer Leaflet (Wolters Kluwer)
- Minoxidil Monograph (AHFS DI)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.